HUTCHMED (China) analyst ratings
HUTCHMED (China) analyst ratings
| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 08/09/2022 | 14.86% | Goldman Sachs | $14 → $16 | Maintains | Neutral |
| 08/02/2022 | 0.5% | Goldman Sachs | $16 → $14 | Maintains | Neutral |
| 09/22/2021 | 230.22% | Goldman Sachs | → $46 | Downgrades | Buy → Neutral |
| 08/03/2021 | 273.3% | Jefferies | → $52 | Initiates Coverage On | → Buy |
| 03/13/2020 | — | Cantor Fitzgerald | Initiates Coverage On | → Overweight | |
| 02/20/2020 | 172.79% | Goldman Sachs | → $38 | Initiates Coverage On | → Buy |
| 11/19/2019 | — | CLSA | Initiates Coverage On | → Buy | |
| 10/23/2019 | — | B of A Securities | Reinstates | → Buy | |
| 03/04/2019 | — | Deutsche Bank | Initiates Coverage On | → Buy | |
| 10/17/2017 | 172.79% | Canaccord Genuity | $30 → $38 | Maintains | Buy |
| 日期 | 上行/下行 | 分析公司 | 目标价格变动 | 评级变动 | 之前/当前的评级 |
|---|---|---|---|---|---|
| 08/09/2022 | 14.86% | 高盛 | 14 美元 → 16 美元 | 维护 | 中立 |
| 08/02/2022 | 0.5% | 高盛 | 16 美元 → 14 美元 | 维护 | 中立 |
| 2021 年 9 月 22 日 | 230.22% | 高盛 | → 46 美元 | 降级 | 买入 → 中性 |
| 08/03/2021 | 273.3% | 杰富瑞集团 | → 52 美元 | 启动覆盖范围开启 | → 购买 |
| 03/13/2020 | — | 坎托·菲茨杰拉德 | 启动覆盖范围开启 | → 超重 | |
| 02/20/2020 | 172.79% | 高盛 | → 38 美元 | 启动覆盖范围开启 | → 购买 |
| 11/19/2019 | — | CLSA | 启动覆盖范围开启 | → 购买 | |
| 2019 年 10 月 23 日 | — | B of A 类证券 | 恢复 | → 购买 | |
| 03/04/2019 | — | 德意志银行 | 启动覆盖范围开启 | → 购买 | |
| 10/17/2017 | 172.79% | Canaccord Genu | 30 美元 → 38 美元 | 维护 | 买 |
HUTCHMED (China) Questions & Answers
和黄医药（中国）问题与解答
The latest price target for HUTCHMED (China) (NASDAQ: HCM) was reported by Goldman Sachs on August 9, 2022. The analyst firm set a price target for $16.00 expecting HCM to rise to within 12 months (a possible 14.86% upside). 3 analyst firms have reported ratings in the last year.
高盛于2022年8月9日公布了和黄医药（中国）（纳斯达克股票代码：HCM）的最新目标股价。该分析公司将目标股价定为16.00美元，预计HCM将在12个月内上涨至12个月（可能上涨14.86％）。去年有3家分析公司公布了评级。
The latest analyst rating for HUTCHMED (China) (NASDAQ: HCM) was provided by Goldman Sachs, and HUTCHMED (China) maintained their neutral rating.
和黄医药（中国）（纳斯达克股票代码：HCM）的最新分析师评级由高盛提供，和黄医药（中国）维持中性评级。
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of HUTCHMED (China), and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for HUTCHMED (China) was filed on August 9, 2022 so you should expect the next rating to be made available sometime around August 9, 2023.
分析师在进行了广泛的研究后得出了股票评级，其中包括浏览公开财务报表，与和黄医药（中国）的高管和客户交谈，以及听取财报电话会议。大多数分析师每三个月做一次这样的评级，因此每家公司每年应该获得4次评级。和黄医药（中国）的最新评级是在2022年8月9日公布的，因此您应该预计下一个评级将在2023年8月9日左右公布。
While ratings are subjective and will change, the latest HUTCHMED (China) (HCM) rating was a maintained with a price target of $14.00 to $16.00. The current price HUTCHMED (China) (HCM) is trading at is $13.93, which is out of the analyst's predicted range.
虽然评级是主观的，而且会发生变化，但和黄医药（中国）（HCM）的最新评级维持不变，目标股价为14.00美元至16.00美元。和黄医药（中国）（HCM）目前的交易价格为13.93美元，超出了分析师的预期区间。